Ameriprise’s Co-Diagnostics CODX Stock Holding History

Ameriprise’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-390	Closed	-$29K	–	3955
2022 Q4	$29K	Sell	390 -190	-33%	-$17.8K	﹤0.01%	3883
2022 Q3	$56K	Sell	580 -197	-25%	-$27.6K	﹤0.01%	3889
2022 Q2	$131K	Hold	777	–	–	﹤0.01%	3743
2022 Q1	$144K	Buy	+777	New	+$161K	﹤0.01%	3808
2021 Q4	–	Sell	-591	Closed	-$172K	–	3972
2021 Q3	$172K	Buy	591 +128	+28%	+$37.4K	﹤0.01%	3723
2021 Q2	$114K	Buy	+463	New	+$119K	﹤0.01%	3807

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ameriprise's CODX Position: Q1 2023 in Review

Ameriprise sold out of Co-Diagnostics (CODX) in Q1 2023, closing a stake of 390 shares — an estimated $29K sold.

Ameriprise first reported a position in CODX in Q2 2021 and held it in 6 quarters. The position peaked at $172K in Q3 2021. 51 funds tracked by Wall St. Rank hold CODX as of Q1 2023.

Ameriprise reported no remaining Co-Diagnostics position as of Q1 2023 after selling out during the quarter.
Ameriprise sold 390 Co-Diagnostics shares in Q1 2023, an estimated $29K.
Ameriprise first reported a position in Co-Diagnostics in Q2 2021 and held it in 6 quarters.
Ameriprise's Co-Diagnostics position peaked at $172K in Q3 2021.
51 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2023.

Based on Ameriprise's 13F filing for Q1 2023, filed 15 May 2023.